secwatch / observer
8-K filed August 30, 2023, 7:59 PM ET ticker MNPR CIK 0001645469
other material confidence high sentiment negative materiality 0.70

Monopar Therapeutics (MNPR): Nasdaq/NYSE listing notice — Monopar receives Nasdaq notice for bid price deficiency; 180 days to regain compliance

Monopar Therapeutics

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Monopar Therapeutics received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange
nasdaq
Notice
deficiency notice
Deficiency
minimum bid price
Rules
5550(a)(2)
Exact text from the filing
August 28, 2023, Monopar Therapeutics Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq Capit
View on SEC.gov

Browse all listing & compliance notices →

Monopar Therapeutics filing history →

Source: SEC EDGAR
accession 0001437749-23-024891
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.